YM-58483/BTP2是钙池调控钙离子进入(SOCE)的阻滞剂,参与调解不可兴奋细胞如淋巴细胞的激活。 溶解性:DMSO : 78 mg/mL (185.1 mM)Ethanol : 78 mg/mL (185.1 mM) 体外研究: YM-58483 (also known as BTP2) is a selective SOCE blocker that inhibits
YM 58483 is a blocker of store-operated Ca2+entry (SOCE), which mediates the activation of non-excitable cells (e.g. lymphocytes). Inhibits calcium release-activated calcium (CRAC) channels; suppressesthapsigargin-induced sustained Ca2+influx (IC50= 100 nM). Displays immuno-modulatory and anti-...
YM-58483/BTP2 is a blocker of store-operated Ca 2+ entry (SOCE), which regulates the activation of non-excitable cells such as lymphocytes. YM-58483 has been reported to inhibit cytokine production and proliferation in T cells, and to be useful as a probable medicinal candidate for ...
YM-58483 (BTP2) 是一种有效的 CRAC channels 抑制剂,能够抑制 Ca2+ 信号。YM-58483 阻断钙池操纵的阳离子内流 (SOCE)。 详细介绍 产品活性:YM-58483 (BTP2) 是一种有效的 CRAC channels 抑制剂,能够抑制 Ca2+ 信号。YM-58483 阻断钙池操纵的阳离子内流 (SOCE)。 品牌介绍: MCE (MedChemExpress) 拥有...
基本信息 YM-58483(BTP2)是选择性(SOCE)阻断剂,,在Jurkat T细胞中抑制anti-CD3抗体所诱导的持续性钙离子流入。 CAS 223499-30-7 分子量 421.32 分子式 C15H9F6N5OS 溶剂 DMSO 纯度 98% 存储温度 -20℃ 相关说明文档 产品使用指南.pdf
YM-58483 (BTP2) 是一种 CRAC channels 抑制剂,能够抑制 Ca2+ 信号。 产品性质 英文别名(English Synonym) YM-58483 中文名称(Chinese Name) / 靶点(Target) SOCE 通路(Pathway) Membrane Transporter/Ion Channel CAS号(CAS NO.) 223499-30-7 分子式(Formula) ...
产品活性:YM-58483 (BTP2) 是一种有效的 CRAC channels 抑制剂,能够抑制 Ca2+ 信号。YM-58483 阻断钙池操纵的阳离子内流 (SOCE)。 生物活性:YM-58483 (BTP2) 是第一个选择性且有效的CRAC 通道和随后的 Ca2+信号[1]抑制剂。 YM-584832 是存储操作的 Ca2+进入 (SOCE)[2]的阻断剂。体外实验:YM-58483...
YM-58483 CAS No. : 223499-30-7 MCE 站:YM-58483 产品活性:YM-58483 (BTP2) 是一种有效的 CRAC channels 抑制剂,能够抑制 Ca2+ 信号。YM-58483 阻断钙池操纵的阳离子内流 (SOCE)。 研究领域:Membrane Transporter/Ion Channel 作用靶点:CRAC Channel In Vitro: YM-58483 can decrease the levels of P...
英文名: YM-58483描述: YM-58483 (BTP2) 是一种特异性有效的 CRAC 通道和随后的 Ca2+ 信号抑制剂,可阻断钙池操纵的阳离子内流 (SOCE)。细胞实验: Jurkat cells (1×107 cells/ml) were tested with varying concentration of compounds for 30 min at 37°C. The cells were stimulated with 1 μM ...
Since YM-58483 inhibits two major characteristic symptoms of bronchial asthma, namely bronchoconstriction and AHR via the suppression of inflammatory mediator and cytokine production, SOCE inhibition is a potential approach for treatment.doi:10.1016/j.pupt.2007.09.003Keiko Ohga...